The Carboxy Terminal Region of the Human Cytomegalovirus Immediate Early 1 (IE1) Protein Disrupts Type II Inteferon Signaling
<p>Diminished interferon-induced gene expression in human fibroblasts expressing IE1. MRC-5 fibroblasts were nucleofected with plasmid pIE622 harboring the <span class="html-italic">UL123</span> gene specifying IE1, or the pFIN2 empty vector. At 24 hours post-nucleofection, the cells were exposed to 100 U/mL of IFNγ or were left untreated. At 6 hours after treatment, total RNA was isolated and subjected to Real Time RT-PCR analysis as described in Materials and Methods. The fold increase in CIITA (<b>A</b>) (<span class="html-italic">p</span> value = 0.053) or IRF1 (<b>B</b>) (<span class="html-italic">p</span> value 0.017) transcript levels in IFN treated cells relative to untreated cells was determined by the ΔΔCt method. Data shown are the average of three independent experiments.</p> "> Figure 2
<p>The carboxy-terminal region of IE1 is required for disruption of IFNγ signaling. (<b>A</b>) Schematic of the IE1 protein and truncation mutants generated in this study. Top line: a schematic of the IE1 protein indicating the amino acid positions comprising the coding exons (below) and the positions of the known functional domains (above). The coding exons are shown in white boxes. The functional domains of exon 4 are shown in shaded boxes and include the leucine zipper (L), the zinc finger (ZF) and the acidic domain (AD). A schematic of the five different IE1 N-terminal truncation mutants generated in this study are shown below. The sixth mutant is a C-terminal truncation mutant. The designation of the plasmids harboring the truncation mutants is based on the deletion of relevant exons or functional domains shown on the right, and the deleted amino acid residues are shown in parentheses. The gene sequences were inserted in frame to sequences specifying a FLAG epitope (depicted as a flag). (<b>B</b>) Interferon Stimulated Gene (ISG) induction in fibroblasts expressing truncated IE1 proteins<b>. </b>The indicated plasmids were nucleoporated into MRC5 cells and 24 hours after nucleofection the cells were treated with 100 U/mL IFNγ. At 6 hours after treatment total RNA was isolated. Real Time RT-PCR analysis was carried out for CIITA and 18S rRNA (endogenous control). The fold increase in CIITA transcript levels in IFN treated cells relative to untreated cells was determined by the ΔΔCt method. Shown is the average of two independent experiments. A film image of immunoblot analysis is shown below. In replicate cultures of the first experiment, cells were treated as above and solubilized. Equal amounts of protein from each lysate were subjected to electrophoresis in a denaturing polyacrylamide gel. Proteins were transferred to nitrocellulose sheets and reacted with the indicated antibodies. Anti-FLAG antibody was used to detect the presence of FLAG tagged IE1 proteins and antibody to GAPDH was used to evaluate protein loading.</p> "> Figure 3
<p>Disruption of ND10 structures in cells expressing IE1 and the C-terminal truncation mutant. Immunofluorescence images of IE1 and Promyelocytic leukemia protein (PML) in fibroblast cells. MRC5 cells were nucleofected with the indicated constructs. At 24 hours after nucleofection cells were fixed in methanol and reacted with mouse monoclonal anti-IE1 antibody (Mab810) followed by anti-mouse alexafluor 488 as secondary antibody. The cells were then exposed to rhodamine conjugated anti PML antibody (PGM3). IE1 reactivity is visualized in green (left column), PML reactivity is visualized in red (middle column) and merged images are shown in the right column.</p> "> Figure 4
<p>IE1 does not alter the state or abundance of key signaling molecules of the IFNγ pathway. Film images of electrophoretically separated cell lysates reacted with antibodies to IFNγ pathway signaling components. MRC5 cells were nucleofected with plasmid harboring full length IE1 (FL), the Δ345–491 C-terminal truncation IE1 (ΔAD) or empty vector (FIN2). At 24 hours after nucleofection, cells were exposed to IFNγ for 30 minutes or left untreated. Cells were solublized and equal amounts of protein from each lysate were subjected to electrophoresis in a denaturing polyacrylamide gel. Proteins were transferred to nitrocellulose sheets and reacted with the indicated antibodies. Anti-FLAG antibody was used to detect the presence of FLAG tagged IE1 proteins and antibody to GAPDH was used to evaluate protein loading.</p> "> Figure 5
<p>Nuclear translocation of STAT1 is not altered by IE1. (<b>A</b>) Immunofluorescence images of IE1 and STAT1 in cells with and without IFNγ treatment. MRC5 cells were nucleofected with the full length IE1 (FL) or empty vector (FIN2). After 24 hours cells were exposed to IFNγ for 30 minutes or left untreated. Cells were fixed in methanol and reacted with mouse monoclonal anti-IE1 antibody (Mab810) and rabbit polyclonal anti‑STAT1 antibody followed by anti-mouse alexafluor 543 and anti-rabbit alexafluor 488 as secondary antibodies. STAT1 reactivity is visualized in green (left column), IE1 reactivity is visualized in red (middle column) and merged images are shown in the right column. (<b>B</b>) Film images of electrophoretically separated cell lysates reacted with antibodies to STAT1 and GAPDH (loading control). MRC5 cells were nucleofected with plasmid harboring full length IE1 (FL), the Δ345–491 C-terminal truncation IE1 (ΔAD) or empty vector (FIN2). At 72 hours after nucleofection, cells were exposed to IFNγ for 30 minutes or left untreated. Cells were harvested and nuclear and cytoplasmic fractions were separated. Equal amounts of protein from the nuclear and cytoplasmic lysates were subjected to electrophoresis in a denaturing polyacrylamide gel. Proteins were transferred to nitrocellulose sheets and reacted with the indicated antibodies.</p> "> Figure 6
<p>Reduced binding of STAT1 to GAS elements in the presence of IE1. Film image of an Electrophoretic Mobility Shift Assay shows a reduction in the amount of IRF1 GAS element probe that is shifted upon mixture with nuclear extracts from MRC5 cells ectopically expressing IE1 (<b>A</b>) and HCMV infected cells (<b>B</b>). In A, MRC5 cells were nucleofected with plasmid harboring full length IE1 (FL), the Δ345–491 C-terminal truncation IE1 (ΔAD) or empty vector (FIN2). At 24 hours after nucleofection, cells were exposed to 100 U/mL of IFNγ or left untreated. At 30 minutes after treatment, cells were solubilized and nuclear extracts were isolated as described in Materials and Methods. Nuclear extracts were mixed with the GAS element of the IRF1 gene with or without addition of unlabeled probe and with or without anti-STAT1 antibody. Resulting complexes were resolved by electrophoresis on a 4.5% native polyacrylamide gel. In a second experiment (<b>B</b>), MRC5 cells were exposed to 1 PFU per cell of the AD169 strain of HCMV or left uninfected. At 12 hours after infection, cells were solubilized and processed as described above. The black arrow indicates the shifted bands and the grey arrow indicates the supershifted bands.</p> "> Figure 7
<p>IE1 does not interact with STAT1 by co-immunoprecipitation. Film images of electrophoretically separated cell lysates and proteins isolated by immunoprecipation. (<b>A</b>) MRC5 cells were exposed to HCMV AD169 at 3 PFU per cell or left untreated. At 12 hours after infection cells were treated with 100 U/mL of IFNγ for 30 minutes. The cells were harvested and solubilized. 350 µg of total protein from each sample was reacted with anti‑IE1 antibody (mouse monoclonal Mab810). The isolated proteins along with the 10 µg total lysates were resolved by denaturing PAGE and transferred to a nitrocellulose membrane. The membrane was reacted with antibodies for STAT1, IE1 and STAT2 and the antibody reactive bands were visualized by chemiluminescence. The left panel shows films exposed for 10 seconds and the right panel shows films exposed for 5 minutes. The arrow indicates the position of the isolated, full length IE1. (<b>B</b>) MRC5 cells were nucleofected with full length IE1 (FL), the Δ345–491 C-terminal truncation IE1 (ΔAD) or empty vector (FIN2). 48 hours after nucleofection cells were exposed to 100 U/mL of IFNγ for 30 minutes. The preparation of cell lysates, immunoprecipitations, PAGE and western hybridization and detection were carried out as above. The left panel shows films exposed for 10 seconds and the right panel shows films exposed for 5 minutes. The short and long arrows indicate the position of the Δ345–491 IE1 in the total lysate and immunoprecipitates respectively.</p> "> Figure 8
<p>Phosphorylated STAT2 does not accumulate in the nucleus of IFNγ-treated MRC-5 cells. Film images of electrophoretically separated nuclear lysates reacted with antibodies to p-STAT2 and Lamin (loading control). MRC5 cells were nucleofected with full length IE1 (FL), the Δ345–491 C-terminal truncation IE1 (ΔAD) or empty vector (FIN2). At 72 hours after nucleofection, cells were exposed to IFNγ or IFNβ for 30 minutes or left untreated. Cells were harvested and nuclear and cytoplasmic fractions were separated. Equal amounts of protein from the nuclear lysates were subjected to electrophoresis in a denaturing polyacrylamide gel. Proteins were transferred to nitrocellulose sheets and reacted with the indicated antibodies.</p> ">
Abstract
:1. Introduction
2. Results and Discussion
2.1. The HCMV IE1 Gene Disrupts Signaling by Type II Interferon
2.2. Mapping of the IE1 Protein Region Involved in Disruption of IFN-Induced Gene Expression
2.3. Disruption of IFNγ Signaling by IE1 Does Not Involve Interaction with PML
2.4. IE1 Does Not Perturb Initial Events in IFNγ-Mediated Signal Transduction
2.5. Type II Interferon-Induced Binding of STAT1 to GAS Elements Is Reduced in the Presence of IE1
2.6. STAT1 Fails to Co-Immunoprecipitate with IE1
3. Experimental Section
3.1. Cells and Viruses
3.2. Transfection, Nucleofection and Infection
3.3. Immunoblotting and Immunoprecipitation
3.4. Flow Cytometry
3.5. Real Time RT-PCR
3.6. Microscopy
3.7. Electrophoretic Mobility Shift Assay (EMSA)
4. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References and Notes
- Vancikova, Z.; Dvorak, P. Cytomegalovirus infection in immunocompetent and immunocompromised individuals—A review. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2001, 1, 179–187. [Google Scholar] [CrossRef]
- Britt, W.J.; Alford, C. A Cytomegalovirus. In Fields Virology; Fields, B., Knipe, D.M., Howley, P.M., Eds.; Lippincott-Raven: Philadelphia, PA, USA, 1996; Volume 2, pp. 2493–2523. [Google Scholar]
- Borden, E.C.; Sen, G.C.; Uze, G.; Silverman, R.H.; Ransohoff, R.M.; Foster, G.R.; Stark, G.R. Interferons at age 50: Past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 2007, 6, 975–990. [Google Scholar] [CrossRef]
- Samuel, C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14, 778–809, table of contents. [Google Scholar] [CrossRef]
- Goodbourn, S.; Didcock, L.; Randall, R.E. Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 2000, 81, 2341–2364. [Google Scholar]
- Le Bon, A.; Tough, D.F. Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev. 2008, 19, 33–40. [Google Scholar] [CrossRef]
- Stetson, D.B.; Medzhitov, R. Type I interferons in host defense. Immunity 2006, 25, 373–381. [Google Scholar] [CrossRef]
- Platanias, L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5, 375–386. [Google Scholar] [CrossRef]
- Schindler, C.; Levy, D.E.; Decker, T. JAK-STAT signaling: From interferons to cytokines. J. Biol. Chem. 2007, 282, 20059–20063. [Google Scholar] [CrossRef]
- Stark, G.R.; Kerr, I.M.; Williams, B.R.; Silverman, R.H.; Schreiber, R.D. How cells respond to interferons. Annu. Rev. Biochem. 1998, 67, 227–264. [Google Scholar] [CrossRef]
- Der, S.D.; Zhou, A.; Williams, B.R.; Silverman, R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 1998, 95, 15623–15628. [Google Scholar]
- Taylor, R.T.; Bresnahan, W.A. Human cytomegalovirus immediate-early 2 protein IE86 blocks virus-induced chemokine expression. J. Virol. 2006, 80, 920–928. [Google Scholar] [CrossRef]
- Taylor, R.T.; Bresnahan, W.A. Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced beta interferon production. J. Virol. 2005, 79, 3873–3877. [Google Scholar] [CrossRef]
- Taylor, R.T.; Bresnahan, W.A. Human cytomegalovirus IE86 attenuates virus- and tumor necrosis factor alpha-induced NFkappaB-dependent gene expression. J. Virol. 2006, 80, 10763–10771. [Google Scholar] [CrossRef]
- Amsler, L.; Verweij, M.C.; Defilippis, V.R. The Tiers and Dimensions of Evasion of the Type I Interferon Response by Human Cytomegalovirus. J. Mol. Biol. 2013, 425, 4857–4871. [Google Scholar] [CrossRef]
- DeFilippis, V.R. Induction and evasion of the type I interferon response by cytomegaloviruses. Adv. Exp. Med. Biol. 2007, 598, 309–324. [Google Scholar] [CrossRef]
- Marshall, E.E.; Geballe, A.P. Multifaceted evasion of the interferon response by cytomegalovirus. J. Interferon. Cytokine Res. 2009, 29, 609–619. [Google Scholar] [CrossRef]
- Powers, C.; DeFilippis, V.; Malouli, D.; Fruh, K. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol. 2008, 325, 333–359. [Google Scholar]
- Vandevenne, P.; Sadzot-Delvaux, C.; Piette, J. Innate immune response and viral interference strategies developed by human herpesviruses. Biochem. Pharmacol. 2010, 80, 1955–1972. [Google Scholar] [CrossRef]
- Loenen, W.A.; Bruggeman, C.A.; Wiertz, E.J. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin. Immunol. 2001, 13, 41–49. [Google Scholar] [CrossRef]
- Paulus, C.; Krauss, S.; Nevels, M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. USA 2006, 103, 3840–3845. [Google Scholar] [CrossRef]
- Krauss, S.; Kaps, J.; Czech, N.; Paulus, C.; Nevels, M. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J. Virol. 2009, 83, 12854–12870. [Google Scholar] [CrossRef]
- Huh, Y.H.; Kim, Y.E.; Kim, E.T.; Park, J.J.; Song, M.J.; Zhu, H.; Hayward, G.S.; Ahn, J.H. Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J. Virol. 2008, 82, 10444–10454. [Google Scholar] [CrossRef]
- Le, V.T.; Trilling, M.; Wilborn, M.; Hengel, H.; Zimmermann, A. Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J. Gen. Virol. 2008, 89, 2416–2426. [Google Scholar] [CrossRef]
- Popkin, D.L.; Watson, M.A.; Karaskov, E.; Dunn, G.P.; Bremner, R.; Virgin, H.W.T. Murine cytomegalovirus paralyzes macrophages by blocking IFN gamma-induced promoter assembly. Proc. Natl. Acad. Sci. USA 2003, 100, 14309–14314. [Google Scholar]
- Zimmermann, A.; Trilling, M.; Wagner, M.; Wilborn, M.; Bubic, I.; Jonjic, S.; Koszinowski, U.; Hengel, H. A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J. Exp. Med. 2005, 201, 1543–1553. [Google Scholar] [CrossRef]
- Le Roy, E.; Muhlethaler-Mottet, A.; Davrinche, C.; Mach, B.; Davignon, J.L. Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression. J. Virol. 1999, 73, 6582–6589. [Google Scholar]
- Miller, D.M.; Zhang, Y.; Rahill, B.M.; Kazor, K.; Rofagha, S.; Eckel, J.J.; Sedmak, D.D. Human cytomegalovirus blocks interferon-gamma stimulated up-regulation of major histocompatibility complex class I expression and the class I antigen processing machinery. Transplantation 2000, 69, 687–690. [Google Scholar]
- Miller, D.M.; Rahill, B.M.; Boss, J.M.; Lairmore, M.D.; Durbin, J.E.; Waldman, J.W.; Sedmak, D.D. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 1998, 187, 675–683. [Google Scholar] [CrossRef]
- Baron, M.; Davignon, J.L. Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2. J. Immunol. 2008, 181, 5530–5536. [Google Scholar]
- Knoblach, T.; Grandel, B.; Seiler, J.; Nevels, M.; Paulus, C. Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-gamma. PLoS Pathog. 2011, 7, e1002016. [Google Scholar] [CrossRef]
- Stenberg, R.M. The human cytomegalovirus major immediate-early gene. Intervirology 1996, 39, 343–349. [Google Scholar]
- Zhang, G.; Raghavan, B.; Kotur, M.; Cheatham, J.; Sedmak, D.; Cook, C.; Waldman, J.; Trgovcich, J. Antisense transcription in the human cytomegalovirus transcriptome. J. Virol. 2007, 81, 11267–11281. [Google Scholar] [CrossRef]
- Watling, D.; Guschin, D.; Muller, M.; Silvennoinen, O.; Witthuhn, B.A.; Quelle, F.W.; Rogers, N.C.; Schindler, C.; Stark, G.R.; Ihle, J.N.; et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 1993, 366, 166–170. [Google Scholar] [CrossRef]
- Korioth, F.; Maul, G.G.; Plachter, B.; Stamminger, T.; Frey, J. The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. Exp. Cell Res. 1996, 229, 155–158. [Google Scholar] [CrossRef]
- Nevels, M.; Paulus, C.; Shenk, T. Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proc. Natl. Acad. Sci. USA 2004, 101, 17234–17239. [Google Scholar] [CrossRef]
- McCormick, A.L. Control of apoptosis by human cytomegalovirus. Curr. Top. Microbiol. Immunol. 2008, 325, 281–295. [Google Scholar]
- Reinhardt, J.; Smith, G.B.; Himmelheber, C.T.; Azizkhan-Clifford, J.; Mocarski, E.S. The carboxyl-terminal region of human cytomegalovirus IE1491aa contains an acidic domain that plays a regulatory role and a chromatin-tethering domain that is dispensable during viral replication. J. Virol. 2005, 79, 225–233. [Google Scholar] [CrossRef]
- Wilkinson, G.W.; Kelly, C.; Sinclair, J.H.; Rickards, C. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. J. Gen. Virol. 1998, 79, 1233–1245. [Google Scholar]
- Ahn, J.H.; Hayward, G.S. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 1997, 71, 4599–4613. [Google Scholar]
- Ahn, J.H.; Brignole, E.J., 3rd.; Hayward, G.S. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol. Cell Biol. 1998, 18, 4899–4913. [Google Scholar]
- Ahn, J.H.; Hayward, G.S. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology 2000, 274, 39–55. [Google Scholar] [CrossRef]
- Xu, Y.; Ahn, J.H.; Cheng, M.; apRhys, C.M.; Chiou, C.J.; Zong, J.; Matunis, M.J.; Hayward, G.S. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression. J. Virol. 2001, 75, 10683–10695. [Google Scholar]
- Chee, A.V.; Lopez, P.; Pandolfi, P.P.; Roizman, B. Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J. Virol. 2003, 77, 7101–7105. [Google Scholar] [CrossRef]
- Tavalai, N.; Papior, P.; Rechter, S.; Leis, M.; Stamminger, T. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 2006, 80, 8006–8018. [Google Scholar] [CrossRef]
- Tavalai, N.; Papior, P.; Rechter, S.; Stamminger, T. Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J. Virol. 2008, 82, 126–137. [Google Scholar] [CrossRef]
- Lee, H.R.; Kim, D.J.; Lee, J.M.; Choi, C.Y.; Ahn, B.Y.; Hayward, G.S.; Ahn, J.H. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J. Virol. 2004, 78, 6527–6542. [Google Scholar] [CrossRef]
- Nusinzon, I.; Horvath, C.M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. USA 2003, 100, 14742–14747. [Google Scholar] [CrossRef]
- Leonard, G.T.; Sen, G.C. Effects of adenovirus E1A protein on interferon-signaling. Virology 1996, 224, 25–33. [Google Scholar] [CrossRef]
- Leonard, G.T.; Sen, G.C. Restoration of interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein. J. Virol. 1997, 71, 5095–5101. [Google Scholar]
- Barnard, P.; McMillan, N.A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999, 259, 305–313. [Google Scholar] [CrossRef]
- Wu, M.; Xu, Y.; Lin, S.; Zhang, X.; Xiang, L.; Yuan, Z. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J. Gen. Virol. 2007, 88, 3260–3269. [Google Scholar] [CrossRef]
- Weihua, X.; Ramanujam, S.; Lindner, D.J.; Kudaravalli, R.D.; Freund, R.; Kalvakolanu, D.V. The polyoma virus T antigen interferes with interferon-inducible gene expression. Proc. Natl. Acad. Sci. USA 1998, 95, 1085–1090. [Google Scholar]
- Morrison, T.E.; Mauser, A.; Wong, A.; Ting, J.P.; Kenney, S.C. Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity 2001, 15, 787–799. [Google Scholar] [CrossRef]
- Chee, A.V.; Roizman, B. Herpes simplex virus 1 gene products occlude the interferon signaling pathway at multiple sites. J. Virol. 2004, 78, 4185–4196. [Google Scholar] [CrossRef]
- Yokota, S.; Yokosawa, N.; Kubota, T.; Suzutani, T.; Yoshida, I.; Miura, S.; Jimbow, K.; Fujii, N. Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and janus kinases during an early infection stage. Virology 2001, 286, 119–124. [Google Scholar] [CrossRef]
- Yokota, S.; Yokosawa, N.; Okabayashi, T.; Suzutani, T.; Miura, S.; Jimbow, K.; Fujii, N. Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway. J. Virol. 2004, 78, 6282–6286. [Google Scholar] [CrossRef]
- Johnson, K.E.; Song, B.; Knipe, D.M. Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. Virology 2008, 374, 487–494. [Google Scholar] [CrossRef]
- Liang, L.; Roizman, B. Expression of gamma interferon-dependent genes is blocked independently by virion host shutoff RNase and by US3 protein kinase. J. Virol. 2008, 82, 4688–4696. [Google Scholar] [CrossRef]
- Wentworth, B.B.; French, L. Plaque assay of cytomegalovirus strains of human origin. Proc. Soc. Exp. Biol. Med. 1970, 135, 253–258. [Google Scholar] [CrossRef]
- Raghavan, B.Z.G.; Kotur, M.; Cheatham, J.; Trgovcich, J. Superiority of Fugene HD transfection reagent in minimizing non-specific cellular interferon responses. Roche Biochemica 2006, 3, 20–23. [Google Scholar]
- CELLQuest Software Reference Manual, Becton Dickinson: San Jose, CA, USA, 1998.
- Beresford, G.W.; Boss, J.M. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat. Immunol. 2001, 2, 652–657. [Google Scholar] [CrossRef]
- Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
- LSM 5 Software, Version 3.5; Carl Zeiss, Inc.: Jena, Germany, 2006.
- Khan, S.; Zimmermann, A.; Basler, M.; Groettrup, M.; Hengel, H. A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J. Virol. 2004, 78, 1831–1842. [Google Scholar] [CrossRef]
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Raghavan, B.; Cook, C.H.; Trgovcich, J. The Carboxy Terminal Region of the Human Cytomegalovirus Immediate Early 1 (IE1) Protein Disrupts Type II Inteferon Signaling. Viruses 2014, 6, 1502-1524. https://doi.org/10.3390/v6041502
Raghavan B, Cook CH, Trgovcich J. The Carboxy Terminal Region of the Human Cytomegalovirus Immediate Early 1 (IE1) Protein Disrupts Type II Inteferon Signaling. Viruses. 2014; 6(4):1502-1524. https://doi.org/10.3390/v6041502
Chicago/Turabian StyleRaghavan, Bindu, Charles H. Cook, and Joanne Trgovcich. 2014. "The Carboxy Terminal Region of the Human Cytomegalovirus Immediate Early 1 (IE1) Protein Disrupts Type II Inteferon Signaling" Viruses 6, no. 4: 1502-1524. https://doi.org/10.3390/v6041502